391 related articles for article (PubMed ID: 35800371)
1. The complex relationship between multiple drug resistance and the tumor pH gradient: a review.
Koltai T
Cancer Drug Resist; 2022; 5(2):277-303. PubMed ID: 35800371
[TBL] [Abstract][Full Text] [Related]
2. Biophysical aspects of P-glycoprotein-mediated multidrug resistance.
Wadkins RM; Roepe PD
Int Rev Cytol; 1997; 171():121-65. PubMed ID: 9066127
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
4. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
6. Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer.
Cao A; Ma P; Yang T; Lan Y; Yu S; Liu L; Sun Y; Liu Y
Mol Pharm; 2019 Jun; 16(6):2502-2510. PubMed ID: 30998372
[TBL] [Abstract][Full Text] [Related]
7. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
8. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
10. New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.
Dinic J; Podolski-Renic A; Stankovic T; Bankovic J; Pesic M
Curr Pharm Des; 2015; 21(38):5589-604. PubMed ID: 26429711
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.
van den Heuvel-Eibrink MM; Sonneveld P; Pieters R
Int J Clin Pharmacol Ther; 2000 Mar; 38(3):94-110. PubMed ID: 10739113
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
14. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
Karthikeyan S; Hoti SL
Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.
Yuan Y; Liu J; Yu X; Liu X; Cheng Y; Zhou C; Li M; Shi L; Deng Y; Liu H; Wang G; Wang L; Wang Z
Acta Biomater; 2021 Nov; 135():556-566. PubMed ID: 34496281
[TBL] [Abstract][Full Text] [Related]
16. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
17. Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles.
Wang Z; Li X; Wang D; Zou Y; Qu X; He C; Deng Y; Jin Y; Zhou Y; Zhou Y; Liu Y
Acta Biomater; 2017 Oct; 62():144-156. PubMed ID: 28842335
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
19. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
20. What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance?
Roepe PD
Curr Pharm Des; 2000 Feb; 6(3):241-60. PubMed ID: 10637378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
